Compare · DXCM vs IART
DXCM vs IART
Side-by-side comparison of DexCom Inc. (DXCM) and Integra LifeSciences Holdings Corporation (IART): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and IART operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 21.3x IART ($1.32B).
- Over the past year, DXCM is down 9.4% and IART is up 23.4% - IART leads by 32.8 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 7 for IART).
- DXCM has more recent analyst coverage (25 ratings vs 24 for IART).
- Company
- DexCom Inc.
- Integra LifeSciences Holdings Corporation
- Price
- $77.56+6.47%
- $17.15+0.94%
- Market cap
- $28.11B
- $1.32B
- 1M return
- +27.29%
- +26.52%
- 1Y return
- -9.43%
- +23.38%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 26
- 7
- Recent ratings
- 25
- 24
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, hydrocephalus management systems, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, bone and joint fixation implants in the upper and lower extremities, and bone grafts products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest IART
- SEC Form 4 filed by EVP & Chief Commercial Officer Mcbreen Michael J.
- SEC Form 4 filed by President and CEO Essig Stuart
- The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts
- Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
- SEC Form SD filed by Integra LifeSciences Holdings Corporation
- Integra upgraded by Citigroup with a new price target
- Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
- Director Hill Barbara B was granted 24,338 shares, increasing direct ownership by 19% to 151,191 units (SEC Form 4)
- Director Bradley Keith covered exercise/tax liability with 882 shares, decreasing direct ownership by 0.99% to 88,254 units (SEC Form 4)
- SEC Form 4 filed by Director Clay Shaundra